Advertisement

Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study

      ABSTRACT

      Purpose

      This study aimed to show that the efficacy of 1PC111 is superior to that of either ezetimibe or pitavastatin alone (monotherapy) for the treatment of hypercholesterolemia.

      Methods

      This was a multicenter, randomized, double-blind, Phase III study. Patients with hypercholesterolemia or mixed dyslipidemia were randomized to receive 1PC111 (which was a fixed-dose combination of pitavastatin 2 mg and ezetimibe 10 mg), pitavastatin 2 mg, or ezetimibe 10 mg daily for 12 weeks. The primary end point was the difference in the percent change in LDL-C from baseline to week 12 between the 1PC111 and each monotherapy group. The secondary end points were the percent change in other lipid profiles from baseline to each visit. All patients were assessed for adverse events until end of study.

      Findings

      A total of 388 patients were randomly assigned to the 1PC111 (n = 128), pitavastatin (n = 132), or ezetimibe (n = 128) group. Generally, baseline characteristics were similar among the 3 groups. A statistically significant decrease in the LDL-C level at week 12 was observed in the 1PC111 group (–50.50% [14.9%]) compared with either the pitavastatin (–36.11% [11.4%]; P < 0.001) or ezetimibe (–19.85% [12.4%]; P < 0.001) group. Also, there was a statistically significant difference between 1PC111 and each monotherapy group in the reduction in total cholesterol, non–HDL-C, and apolipoprotein B levels. Moreover, there was a trend toward more efficient lowering of LDL-C levels in elderly patients (age ≥65 years) than in younger patients (age <65 years) by 1PC111 treatment. In patients given a class I recommendation for atherosclerotic cardiovascular disease prevention, the percentage of patients achieving the LDL-C target of <100 mg/dL at week 12 was significantly higher in the 1PC111 group than in both monotherapy groups (P < 0.001). Overall, the incidence of adverse events was similar among 3 groups.

      Implications

      1PC111 was more effective in improving lipid profiles and achieving the LDL-C goal than pitavastatin or ezetimibe alone for hypercholesterolemia treatment. Furthermore, 1PC111 may provide more benefit in treating elderly patients. ClinicalTrials.gov identifier: NCT04643093.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pol Tymon
        • et al.
        Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy: insights from the ARISTOTLE (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation) trial.
        J Am Heart Assoc. 2018; 7e007444
        • Shepherd James
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1308
        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344 (8934): 1383-1389
        • Ference Brian A.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur Heart J. 2017; 38: 2459-2472
        • Saito Yasushi.
        Pitavastatin: an overview.
        Atheroscler Suppl. 2011; 12: 271-276
        • Yokote Koutaro
        • et al.
        Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis.
        Expert Rev Cardiovasc Ther. 2011; 9: 555-562
        • Reiner Željko
        • et al.
        ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
        Eur Heart J. 2011; 32: 1769-1818
        • Arnett Donna K.
        • et al.
        2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Journal of the American College of Cardiology. 2019; 74: 1376-1414
        • Choi Young Hwan
        • et al.
        Influence of previous statin therapy on cholesterol-lowering effect of ezetimibe.
        Korean Circ J. 2014; 44: 227-232
        • Cannon Christopher P.
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N Engl J Med. 2015; 372: 2387-2397
        • Euroaspire I.I.
        Lifestyle and risk-factor management and use of drug therapies in coronary patients from 15 countries.
        Eur. Heart J. 2001; 22: 554-572
        • Yang Young-June
        • et al.
        Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk.
        Clin. Ther. 2017; 39: 107-117
      1. 2020 US FDA approved label of LIPTRUZET®.

      2. 2020 US FDA approved label of VYTORIN®.

      3. 2021 US FDA approved label of ROSZET®.

        • Mach Francois
        • et al.
        2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
        Atherosclerosis. 2019; 290: 140-205
        • Yazdanyar Ali
        • Newman Anne B.
        The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs.
        Clin Geriatr Med. 2009; 25: 563-577
        • Ramkumar Satish
        • Raghunath Ajay
        • Raghunath Sudhakshini
        Statin therapy: review of safety and potential side effects.
        Acta Cardiol Sin. 2016; 32: 631
        • Núñez-Cortés Millán
        • Jesús
        • et al.
        Consensus on the statin of choice in patients with impaired glucose metabolism: results of the DIANA Study.
        Am J Cardiovasc Drugs. 2017; 17: 135-142
        • Thom Simon
        • et al.
        Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
        JAMA. 2013; 310: 918-929